Genexine Enters into Clinical Research Collaboration with MSD

Genexine Enters into Clinical Research Collaboration with MSD


Genexine , a clinical stage biotechnology company developing innovative biologics, today announced that it has entered into a clinical research collaboration with Merck & Co., Inc. , Kenilworth, NJ, USA , for the assessment of Genexine's GX-188E, HPV therapeutic DNA vaccine, in combination with MSD's anti-PD-1 therapy, KeytrudaA , for the treatment of patients with HPV-induced cancers. Under the terms of the agreement between Genexine and MSD, through a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, Genexine will conduct a Phase 1b/2a clinical trial to access safety and efficacy of the combination therapy, and MSD will provide clinical supplies of Keytruda and offer support to the study.



from Biotech News